Positive phase IIb data for BAF312 (siponimod) in MS
Positive phase IIb data for BAF312 (siponimod) in MS
At the 64th annual meeting of the American Academy of Neurology (AAN) Novartis will present the key results from a phase II dose finding study of its investigational compound BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5 (S1P1, 5-R modulator), in MS.
This double-blind placebo-controlled study applied an innovative adaptive trial design to optimally describe the dose response relationship.
A statistically significant dose response relationship could be established....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post